News

Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now
Biotech company Alnylam Pharmaceuticals conceded defeat for now in a lawsuit against Pfizer and BioNTech over technology in ...
Jim Cramer on Pfizer (PFE) – “Caught in a Vortex, but I’m Sticking with Seagen and Dr. Bourla”
We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at ...
Drug Price Regulations: Is Pfizer Stock A Buy Or Sell?
Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...
Wondering if Pfizer's 7.6% Dividend Yield Is Sustainable? Here's What You Need to Know.
But when a dividend yield reaches ultrahigh levels, investors can feel a heightened level of uncertainty. Wondering if Pfizer ...
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
Drugmakers' shares fell globally after President Trump said he would [sign an executive order]( ...
MedPage Today on MSN1d
Pfizer Confirms: Leading JAK Inhibitor Often Comes With Weight Gain
Patients taking tofacitinib (Xeljanz) in the drug's late-stage and post-marketing studies were more likely than those on ...
Explore more
Pfizer subsidiary receives A2 rating from Moody’s with stable outlook
Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...
Pfizer: Bearish Catalysts Brewing
Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...